Conclusion: The use of rosiglitazone may be associated with a decline of renal function in patients with T2DM. Further studies are needed to better quantify the risk-benefit trade-offs associated with rosiglitazone therapy.
PMID: 20155725 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)